title: [Result of phase II clinical trial of herceptin in advanced Chinese breast cancer patients].
abstract: OBJECTIVE
  To observe the clinical efficacy and adverse effects of herceptin for advanced Chinese breast cancer patients.
  
  
  METHODS
  Thirty-one pathologically proved advanced breast cancer women were treated by herceptin. In the first week, a loading dose 4 mg/kg was administered by intravenous infusion and from the second week, a routine dose of 2 mg/kg was given every week for at least 3 months.
  
  
  RESULTS
  There were 2 CR, 6 PR, 7 SD, and 16 PD among 31 patients after treatment by herceptin, the response rate being 25.8%. In factors influencing the prognosis, age and general condition were factors favoring the results, and pathological type, site of metastasis, grade of her-2 over expression and prior treatment were irrelevant to the results. The adverse effects were mild but different from those of the common anticancer drugs.
  
  
  CONCLUSIONS
  Herceptin is effective and well tolerated by the Chinese breast cancer patients.
authors.affiliation: Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Li-qing
authors.initials: LQ
authors.lastname: Li
authors.forename: San-tai
authors.initials: ST
authors.lastname: Song
authors.forename: Li-gong
authors.initials: LG
authors.lastname: Xu
authors.forename: Shi-ying
authors.initials: SY
authors.lastname: Yu
authors.forename: Jin-wan
authors.initials: JW
authors.lastname: Wang
authors.forename: Ze-fei
authors.initials: ZF
authors.lastname: Jiang
authors.forename: Ji-liang
authors.initials: JL
authors.lastname: Yin
authors.forename: Hui-hua
authors.initials: HH
authors.lastname: Xiong
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab